Clinical Trial Update: A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating emvododstat (PTC299) for hospitalized COVID-19 pneumonia has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• emvododstat (PTC299)

Snippet

Sponsor: PTC Therapeutics | Conditions: Pneumonia, COVID-19 | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2023-06-26